[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368453-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-368453-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","cd44v-s1pr1-her3-met-and-cancer-associated-amino-acid-transporters-are-promising-targets-for-pancreatic-cancer","CD44v, S1PR1, HER3, MET and Cancer-Associated Amino Acid Transporters are Promising Targets for Pancreatic Cancer","","Research evaluates CD44v, S1PR1, HER3, MET, and cancer-associated amino acid transporters as diagnostic and therapeutic targets for pancreatic ductal adenocarcinoma (PDAC). Novel rat monoclonal antibodies against membrane proteins were used with flow cytometry and immunohistochemistry. Key receptors and transporters, including HER1–4, MET, S1PR1, LAT1, xCT, ASCT2, CAT1, and CD44v, were expressed at high frequencies in vitro and in vivo PDAC. Antibody internalization and toxin-linked growth inhibition were shown across multiple PDAC cell lines, and antibodies targeting S1PR1, ASCT2, HER3, and CD44v inhibited growth of xenografted MIA PaCa-2 tumors. CD44v-high PDAC correlated with elevated HER1–3 and MET mRNA and poor prognosis, supporting their promise for PDAC management.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cd44v-s1pr1-her3-met-and-cancer-associated-amino-acid-transporters-are-promising-targets-for-pancreatic-cancer/368453/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cd44v-s1pr1-her3-met-and-cancer-associated-amino-acid-transporters-are-promising-targets-for-pancreatic-cancer/368453.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Which targets were evaluated for pancreatic ductal adenocarcinoma (PDAC)?","Question",{"text":63,"@type":64},"The study evaluated CD44v, S1PR1, HER3, MET, and multiple cancer-associated amino acid transporters, including LAT1, xCT, ASCT2, and CAT1.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the PDAC cells analyzed and how did the antibodies work?",{"text":68,"@type":64},"PDAC was analyzed using flow cytometry and immunohistochemistry. The antibodies showed internalization of membrane proteins and, when toxin-linked, inhibited growth in PDAC cell lines.",{"name":70,"@type":61,"acceptedAnswer":71},"What was observed in xenografted PDAC models?",{"text":72,"@type":64},"Monoclonal antibodies against S1PR1, ASCT2, HER3, and CD44v inhibited the growth of xenografted MIA PaCa-2 PDAC cells.",{"name":74,"@type":61,"acceptedAnswer":75},"How did CD44v-high PDAC relate to prognosis?",{"text":76,"@type":64},"CD44v-high PDAC displayed high mRNA expression of HER1–3 and MET and was correlated with poor prognosis.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},368453,1790373632,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","RESEARCH ARTICLE  \nCD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb  \nTakashi Nakano 1,2, Kouki Okita 1,3, Shogo Okazaki 1,4 , Soshi Yoshimoto 1,5, Sachiko Masuko 1,5, Hideki Yagi 1,6, Kazunori Kato2, Yoshihisa Tomioka7, Kenichi Imai4 , Yoichi Hamada8,  \nKazue Masuko 1, Kayoko Shimada-Takaura9, Noriaki Nagai3, Hideyuki Saya 10, Tomio Arai 11, Toshiyuki Ishiwata 11 and Takashi Masuko 1,3,10   \n1 Cell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan  \n2 Faculty of Health and Sports Sciences, Toyo University, Kita-ku, Japan  \n3 Advanced Design for Pharmaceuticals, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan  \n4 Department of Microbiology, Division of Immunology and Pathobiology, School of Dentistry, Nihon University, Chiyoda-ku, Japan  \n5 PIERAS Co., Ltd, Osaka-shi, Japan  \n6 Department of Pharmaceuticals, Faculty of Pharmacy, International University of Health and Welfare, Otawara-shi, Japan  \n7 Oncology Pharmacy Practice and Science, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai-shi, Japan  \n8 Hamada Clinic, Higashiosaka-shi, Japan  \n9 Natural Drug Resources, Faculty of Pharmacy, Kindai University, Higashiosaka-shi, Japan  \n10 Oncology Innovation Center, Fujita Health University, Toyoake-shi, Japan  \n11 Division of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Japan  \nKeywords  \namino acid transporter; CD44v; HER3; MET; pancreatic cancer; S1PR1  \nCorrespondence  \nT. Masuko, Advanced Design for Pharmaceuticals, School of Pharmacy, Kindai University, 4-1 Kowakae 3-chome, Higashiosaka-shi, Osaka 577-8502, Japan [E-mail:](E-mail: masuko@phar.kindai.ac.jp)[ masuko@phar.kindai.ac.jp](E-mail: masuko@phar.kindai.ac.jp)  \nTakashi Nakano and Kouki Okita contributed equally to this work.  \nCell Biology Laboratory (April, 2000~) was closed at the end of March, 2020, after the mandatory retirement of Takashi Masuko.  \nEffective therapies have yet to be established for pancreatic ductal adenocarcinomas (PDAC) even though it is the most aggressive cancer. In the present study, PDAC was analyzed using novel rat mAbs against membrane proteins in conjunction with ﬂow cytometry and immunohistochemistry. Human epidermal growth receptor (HER)1–4, mesenchymal to epithelial transition factor (MET), sphingosine-1-phospahate receptor 1  \n(S1PR1), L-type amino acid transporter 1 (LAT1), system x 􀀁 c transporter (xCT), alanine-serine-cysteine transporter (ASCT2), cationic amino acid transporter 1 (CAT1) and variant CD44 (CD44v) were expressed at high frequencies in both in vitro and in vivo PDAC. Internalization of membrane proteins by mAbs and growth inhibition by toxin-linked mAbs were demonstrated in many PDAC cell lines, and mAbs against S1PR1, ASCT2, HER3 and CD44v inhibited the growth of xenografted MIA PaCa-2 PDAC cells. Furthermore, CD44v-high PDAC showed high mRNA expression of HER1–3, MET and CD44v, and was correlated with poor prognosis. Taken together, our results suggest that CD44v, S1PR1, HER3,  \nAbbreviations  \nADCC, antibody-dependent cellular cytotoxicity; ASCT2, alanine-serine-cysteine transporter; CAT1, cationic amino acid transporter 1; CD44v, variant CD44; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; FCM, ﬂow cytometry; GFP, green ﬂuorescent protein; HER, human epidermal growth factor receptor; IHC, immunohistochemistry; LAT1, L-type amino acid transporter; MET, mesenchymal to epithelial transition factor; MFI, mean ﬂuorescence intensity; NEC, neuroendocrine carcinomas; PBMC, peripheral blood mononuclear cell; PBS, phosphate-buffered saline; PE, phycoerythrin; PCA, principal component analysis; PDAC, pancreatic ductaladenocarcinoma; RTK, receptor tyrosine kinase; S1PR1, sphingosine-1-phosphate receptor 1; TCGA, The Cancer Genome Atlas; Tf","cbCaidMDZhKnN468","https://ap.wps.com/l/cbCaidMDZhKnN468","pdf",4314582,18,"English","# Research Article\n## Abstract and Background\n## Experimental Approach and Antibody Targeting\n## Expression Patterns and Functional Effects\n## Prognostic Correlation and Therapeutic Implications","[{\"question\":\"Which targets were evaluated for pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"The study evaluated CD44v, S1PR1, HER3, MET, and multiple cancer-associated amino acid transporters, including LAT1, xCT, ASCT2, and CAT1.\"},{\"question\":\"How were the PDAC cells analyzed and how did the antibodies work?\",\"answer\":\"PDAC was analyzed using flow cytometry and immunohistochemistry. The antibodies showed internalization of membrane proteins and, when toxin-linked, inhibited growth in PDAC cell lines.\"},{\"question\":\"What was observed in xenografted PDAC models?\",\"answer\":\"Monoclonal antibodies against S1PR1, ASCT2, HER3, and CD44v inhibited the growth of xenografted MIA PaCa-2 PDAC cells.\"},{\"question\":\"How did CD44v-high PDAC relate to prognosis?\",\"answer\":\"CD44v-high PDAC displayed high mRNA expression of HER1–3 and MET and was correlated with poor prognosis.\"}]","CD44v, S1PR1, HER3, MET and Cancer-Associated Amino Acid Transporters are Promising Targets for Pancreatic Cancer | PDF",1790177028,45,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95dd6de59552371bccbd3933d50d2d0e.webp",983,1291,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9130a987c6882f3f78b7c7cd3ee416a9.webp",982,1290,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/023d50246746607d10def95a1ffbf191.webp",981,1289,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02b9108b0835a1e2d1426961ae44caba.webp",980,1287]